XML 150 R56.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration Agreements - Composition of the Total Transaction Price (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019
--- | --- | ---
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | $ 87,225 |
Combined 2018 AZ Agreements |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | 396,830 | $ 401,782
Combined 2018 AZ Agreements | Upfront payment |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | 240,000 | 240,000
Combined 2018 AZ Agreements | Sublicense reimbursement |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | 1,000 | 1,000
Combined 2018 AZ Agreements | Milestone payment | Toxicity milestone payment |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | 60,000 | 60,000
Combined 2018 AZ Agreements | Milestone payment | Competition milestone payment |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | 60,000 | 60,000
Combined 2018 AZ Agreements | Estimated Reimbursement |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |
Remaining performance obligations | $ 35,830 | $ 40,782

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_SublicenseReimbursementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_ToxicityMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CompetitionMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_EstimatedReimbursementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |